Distributors of Neurontin, Lyrica, and Celebrex to change

Raises concerns about temporary supply shortages

Viatris and Takeda changes domestic suppliers for their major products

Neurontin, Lyrica, Celebrex seller to change from Jeil to another domestic company

Seller for Dexilant DR and Lanston LFDT Tab may also change…” signs of potential supply shortages

With the transfer of sales rights between domestic pharmaceutical companies for major original products expected, the change is expected to affect not only the pharmaceutical and distribution industries but also front-line pharmacies.

 

According to the pharmaceutical wholesale industry sources on the 13th, the transfer of rights to domestic pharmaceutical companies for some of Viatris and Takeda Pharmaceutical’s products is being confirmed or under discussion in the first quarter of this year.

 

The products for which the recent transfer of rights has been confirmed and related notices are being issued to the pharmaceutical wholesale industry one after another are: Viatris' Neurontin Tab, Neurontin Cap, Lyrica Cap, Lyrica CR Tab, and Celebrex Cap.

 

Their supplier will change from Jeil Pharmaceutical, the current supplier of these products, to a domestic pharmaceutical company on the 4th of next month.

 

With less than a month left for the change of suppliers, some of these products are already in short supply.

 

In the case of Neurontin, no new stock has been supplied to the distribution industry since last month, and the industry believes that the pharmaceutical company has adjusted its supply in anticipation of the change in sales channels.

 

In the pharmaceutical and distribution industries, the change in the supplier of some of Takeda Pharmaceutical’s products is also rising as an issue.

 

According to industry sources, information about the transfer of sales rights of Dexilant DR Cap and Lanston LFDT Tab, which have been supplied by Jeil Pharmaceutical, has spread throughout the industry, with the timing of the change expected around April 1.

 

It is also reported that Dexilant's stock has been rapidly depleted recently.

 

Jeil Pharmaceutical, which is at the center of the issue of changing suppliers, responded, “We are aware that relevant information is circulating in the industry, but it is difficult to confirm the details as it is a sensitive part of our contract.” The pharmaceutical and distribution industries believe that the market will be affected to some extent, as the products for which the change of suppliers is expected are major items.

 

There may be some instability in the supply and demand of related items in the process of transferring sales rights, therefore, pharmacies that handle related items may need to manage their inventory.

 

“Pharmaceutical companies and the distribution industry are keeping a close eye on the situation because the items under discussion are large,” said an official from the wholesale industry.

 

“As the quantity of goods shipped may be adjusted during the process of changing suppliers, there may be temporary instability in the supply and demand of related items.”